Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
UBS
Boehringer Ingelheim
US Department of Justice
Cipla

Generated: August 24, 2019

DrugPatentWatch Database Preview

Litigation Details for Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)

Docket ➤ Sign Up Date Filed 2015-04-27
Court District Court, N.D. Illinois Date Terminated 2016-01-08
Cause 15:1126 Patent Infringement Assigned To Sharon Johnson Coleman
Jury Demand None Referred To
Parties APOTEX INC; DAIICHI SANKYO CO., LTD.; DAIICHI SANKYO, INC.; MYLAN PHARMACEUTICALS INC.
Patents 5,616,599; 6,878,703
Attorneys Autumn N. Nero; C. Austin Ginnings; Daniel R. Cherry; David C. Van Dyke; David L. Anstaett; David R. Pekarek Krohn; Dominick A Conde; Emily Elizabeth Bennett; James B Coughlan; Joshua Calabro; Leonard Friedman; Nina Shreve; Shannon M. Bloodworth; Sherry Lee Rollo; Steven Eric Feldman
Firms Fitzpatrick, Cella, Harper & Scinto; Hahn Loeser & Parks LLP; Howard & Howard; Howard & Howard Attorneys PLLC; Perkins Coie LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Apotex Inc v. Daiichi Sankyo, Inc.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-04-27 1 the expiration of United States Patent No. 5,616,599 (“the ’599 patent”) and any applicable pediatric …-infringement of United States Patent No. 6,878,703 (“the ’703 patent”) to enable Apotex to bring its… PATENT IN SUIT 15. On its face the ’703 patent entitled “Pharmaceutical…United States Patent and Trademark Office on April 12, 2005. A copy of the ’703 patent is attached as…States Patent and Trademark Office, Sankyo Company, Limited is the assignee of the ’703 patent. External link to document
2016-01-08 66 United States Patents Nos. 6,878,703 (the “703 patent”) and 5,616,599 (the “599 patent”) with the FDA…1) no patent information has been filed with the FDA, (2) the patent has expired, (3) the patent will …infringed the ‘599 patent, and Mylan’s Paragraph IV certifications for that patent were thus converted…ANDA infringed on a patent, and that it should not be considered until that patent expired). Mylan’s ANDAs…Paragraph IV certifications as to the ‘703 patent because that patent, although disclaimed, remains listed External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Teva
Accenture
McKesson
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.